Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial)
| Autor: | Katja Weisel, David Berry, Eberhard Gunsilius, Bela Hausmann, Niklas Zojer, Andreas L. Petzer, Martin Schreder, Daniel Lechner, Richard Greil, Stefan Knop, Karl Jochen Krenosz, Hermann Einsele, Heinz Ludwig, Alois Lang, Roman Hájek, Wolfram Pönisch, Alexander Egle |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry mucosal medicine.disease Molecular analysis Ixazomib multiple myeloma chemistry.chemical_compound chemistry Internal medicine Relapsed refractory medicine molecular analysis In patient Oral Microbiome Progression-free survival business Multiple myeloma |
| Zdroj: | eJHaem. 2:99-103 |
| ISSN: | 2688-6146 |
| Popis: | Alterations in the human microbiome have been linked to several malignant diseases. Here, we investigated the oral microbiome of 79 patients with relapsed/refractory multiple myeloma (MM) treated with ixazomib-thalidomide-dexamethasone. Increased alpha diversity (Shannon index) at the phylum level was associated with longer progression-free survival (PFS) (10.2 vs 8.5 months |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text